Knight Therapeutics
As of the edition of 20 October 2026, Knight Therapeutics runs 11 drugs, 11 of them marketed; it is on route A at 0 targets and on route B at 7 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methadone | none listed | 2 |
| Miltefosine | none listed | 0 |
| Dextroamphetamine | none listed | 3 |
| Methoxyflurane | none listed | 0 |
| Fludrocortisone acetate | none listed | 1 |
| Clodronic acid | none listed | 0 |
| Bethanechol | none listed | 3 |
| Zinc oxide | none listed | 0 |
| Clioquinol | none listed | 0 |
| Pizotyline | none listed | 0 |
| Flumethasone pivalate | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 7 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where Knight Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 1 trials led
- Skin and connective tissue: 1 trials led